Invasive vs Conservative management of acute coronary syndromes: Do the data support the guidelines?

JAMA

Volumn 288, Issue 15, 2002, Pages 1905-1907

  Cohen, David J ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DALTEPARIN; HEPARIN; TIROFIBAN; TROPONIN T;

ACUTE DISEASE; ANGIOCARDIOGRAPHY; CONSERVATIVE TREATMENT; EDITORIAL; HEART CATHETERIZATION; HEART MUSCLE ISCHEMIA; HIGH RISK POPULATION; HUMAN; PRIORITY JOURNAL; REVASCULARIZATION; UNSTABLE ANGINA PECTORIS;

EID: 0037120821     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.288.15.1905     Document Type: Editorial

References (14)

1. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guidelines for the management of unstable angina and non-ST-segment elevation myocardial infarction: executive summary and recommendations. Circulation. 2000;102:1193-1209. Available at: http://www.acc.org/clinical/guidelines/unstable/unstable .pdf. Accessed September 4, 2002. Accessibility verified September 16, 2002.
2. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Circulation. 1994;89:1545-1556.
3. Boden WE, O'Rourke RA, Crawford MH, et al, for the Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. N Engl J Med. 1998;338:1785-1792.
4. Fragmin and Fast Revascularization during InStability in Coronary artery disease (FRISC II) Investigators. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet. 1999;354:708-715.
5. Wallentin L, Lagerqvist B, Husted S, et al. Outcome at one year after an invasive compared with a non-invasive strategy in unstable coronary artery disease: the FRISC II invasive randomized trial. Lancet. 2000;356:9-16.
6. Cannon CP, Weintraub WS, Demopoulos LA, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med. 2001;344:1879-1887.
7. Morrow DA, Cannon CP, Rifai N, et al, for the TACTICS-TIMI 18 Investigators. Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. JAMA. 2001;286:2405-2412.
8. McNeil BJ. Hidden barriers to improvement in the quality of care. N Engl J Med. 2001;345:1612-1620.
9. Topol E, Mark D, Lincoff A, et al. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial (EPISTENT). Lancet. 1999;354: 2019-2024.
10. Reynolds MR, Neil N, Ho KKL, et al. Clinical and economic outcomes of multivessel coronary stenting compared with bypass surgery: a single-center US experience. Am Heart J. In press.
11. Mahoney EM, Jurkovitz, CT, Chu H, et al. Cost and cost-effectiveness of an early invasive vs conservative strategy for the treatment of unstable angina and non-ST-segment elevation myocardial infarction. JAMA. 2002;288:1851-1858.
12. Mark DB, Hlatky MA. Medical economics and the assessment of value in cardiovascular medicine, I. Circulation. 2002;106:516-520.
13. Tengs TO, Adams ME, Pliskin JS, Safran DG, Siegel JE, Weinstein MC, Graham JD. Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal. 1995;15:369-390.
14. Goldman L, Gordon DJ, Rifkind BM, et al. Cost and health implications of cholesterol lowering. Circulation. 1992;85:1960-1968.